PHARMACY

GSK submits approval application for albiglutide

BY Alaric DeArment

LONDON — Drug maker GlaxoSmithKline is seeking Food and Drug Administration approval for a new treatment for Type 2 diabetes, the drug maker said.

GSK announced the submission to the FDA of a regulatory approval application for albiglutide. The drug is not approved in any market yet, and the company plans to also seek approval in the European Union this year.

GSK assumed control of albiglutide with its $3.6 billion acquisition of Human Genome Sciences, announced last July.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

NCPA monitoring new state health insurance exchanges

BY John Norton

This will be a big year for implementation of the Patient Protection and Affordable Care Act, and the National Community Pharmacists Association will track the process closely on behalf of NCPA members and the patients they serve. NCPA recently submitted comments about the ACA’s Multi-State Plans, or MSPs, being designed by the Office of Personnel Management.

These MSPs will be offered in every state health insurance exchange and are a subset of the Qualified Health Plans that also will be offered in the exchanges. Specifically, NCPA’s comments called for “restating the PBM reporting requirements” mandated for all exchange plans under the ACA, and implementing “the PBM transparency provisions” that OPM recently put into place for the Federal Employees Health Benefit plan, or FEHBP, for the MSPs in any final rule.

MSPs must comply with the transparency provisions in the ACA regarding retail and mail order pharmacies. Applying that standard universally going forward will help MSPs to both manage the prescription benefit portion of the plan and better calculate “PBM fees into medical/quality expenses versus administrative expenses for the purpose of compliance with the required medical loss ratio calculation.”

Estimates from the PBM transparency provision implemented in 2011 for FEHBP discovered that the drug benefit accounted for one-third of the costs of the entire program. As a result OPM “responded by requiring PBMs that serve the FEHBP to make certain necessary disclosures that go above and beyond those required under the ACA.” NCPA wants that “lessons learned” approach applied to MSPs.

NCPA’s comments also suggested that the minimum pharmacy access standards — like those under Tricare and Medicare Part D — should be required in MSPs, because independent pharmacies are accessible, patient-centered, and offer the safety net of healthcare providers in many communities that are otherwise underserved.

In addition, NCPA urges that OPM not equate mail-order pharmacy with access to the face-to-face interaction of a local pharmacy. In other words, the issue of “limited network capacity in hard-to-serve regions” should not be an excuse for further promotion or incentivizing of mail-order pharmacies, which don’t necessarily meet the needs of all patients. MSPs also should comply with any applicable state provisions such as “any willing provider,” PBM audit, or mandatory mail-order pharmacy laws as well. Finally, NCPA suggested, in the interests of improving health, that MSPs include an annual pharmacist-provided, medication therapy review when appropriate.

NCPA’s efforts have been successful so far in getting standards put in place that work for patients and plan sponsors of prescription drug benefits, along with attempting to level the playing field so that independent pharmacies can continue to compete in the marketplace. We will remain engaged as the process winds its way to completion this year.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

AIDS Healthcare Foundation to rebrand MOMS Pharmacy

BY Alaric DeArment

LOS ANGELES — The AIDS Healthcare Foundation is rebranding a chain of specialty pharmacies it recently bought.

The AHF, which bought MOMS Pharmacy in August 2012, said it would rebrand the chain as AHF Pharmacy. MOMS is focused exclusively on providing medications and support services to people living with HIV and AIDS. The name change will be effective immediately, but the entire rebranding could take several months due to state pharmacy regulations and the need to replace signage, prescription labeling and other fixtures.

"2012 was an exciting year for AHF, heralded by the remarkable growth and expansion of many of our programs and services, including AHF’s acquisition of the MOMS Pharmacy chain in August," AHF president Michael Weinstein said. "Throughout the transition, continuity of care and services for MOMS Pharmacy clients remained our highest priority, so we made a decision to continue to operate those pharmacies under the MOMS brand."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

leejennifer842 says:
Apr-05-2013 12:07 am

MOMS pharmacy mainly deals with medication regarding people suffering from AIDS and HIV. These pharmacies are doing a great job by providing services to the patients against the most dreaded disease in the world. I hope the rebranding would make it more popular and it will continue to provide services like this.

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?